Interesting...I was always under the impression that when you compare your product in a randomized Phase III to an already approved product, the FDA wouldn't want a crossover component. Should be wild 2008.
Interesting post from the IV MB wrt filing a NDA if results of an interinm analysis are statistically significant. With 9902b, Vital-1 and possibly Vital-2 reporting interin results in 2008, it could be an interesting year for cancer immunotherapies.http://www1.investorvillage.com/smbd.asp?mb=971&mn=154080&pt=msg&mid=2940983
Market Data 
Markets 
AI
